Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

BAY 1895344 Plus Topoisomerase-1 (Top1) Inhibitors in Patients With Advanced Solid Tumors, Phase I Studies With Expansion Cohorts in Small Cell Lung Carcinoma (SCLC), Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) and Pancreatic Adenocarcinoma (PDA)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT04514497
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:26:46.523539+00:00
Published At
2025-03-06T00:00:00+00:00
Record Updated At
2025-03-06
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Metastatic Lung Small Cell Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Neuroendocrine Carcinoma", "Metastatic Pancreatic Adenocarcinoma", "Stage III Lung Cancer AJCC v8", "Stage III Pancreatic Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8", "Unresectable Lung Small Cell Carcinoma", "Unresectable Malignant Solid Neoplasm", "Unresectable Neuroendocrine Carcinoma", "Unresectable Pancreatic Adenocarcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-03-06"
protocolSection.identificationModule.nctId
"NCT04514497"
protocolSection.identificationModule.officialTitle
"BAY 1895344 Plus Topoisomerase-1 (Top1) Inhibitors in Patients With Advanced Solid Tumors, Phase I Studies With Expansion Cohorts in Small Cell Lung Carcinoma (SCLC), Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) and Pancreatic Adenocarcinoma (PDA)"
protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Metastatic Lung Small Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Metastatic Malignant Solid Neoplasm (protocolSection.conditionsModule.conditions)
  • Metastatic Neuroendocrine Carcinoma (protocolSection.conditionsModule.conditions)
  • Metastatic Pancreatic Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Stage III Lung Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage III Pancreatic Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage IV Lung Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage IV Pancreatic Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Unresectable Lung Small Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Unresectable Malignant Solid Neoplasm (protocolSection.conditionsModule.conditions)
  • Unresectable Neuroendocrine Carcinoma (protocolSection.conditionsModule.conditions)
  • Unresectable Pancreatic Adenocarcinoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.